Facility expansion at CRO following record year
Additional space will primarily be used to increase laboratory facilities, GMP suites and allocate space for storage of GMP materials.
ONYX Scientific is set to increase the size of its UK-based site by over 30pc following the best performance in the company’s 15-year history.
The contract research organisation (CRO) and small-scale API manufacturer is investing in an additional site located adjacent to its existing facility in North-East England to help its clients accelerate candidates from discovery to production.
Its additional space will primarily be used to increase its laboratory facilities, GMP suites and allocate space for storage of GMP materials.
As part of the expansion initiative, Onyx Scientific has recruited several more chemists to support clients’ pre-clinical, development and early stage API manufacturing projects.
Denise Bowser, commercial director at Onyx Scientific, said: “It’s been a challenging few years for CROs across the industry, but our team has continued to work hard to always exceed clients’ expectations, which has led to a very loyal customer base and regular repeat business.
“Although we have come to the end of a very positive year, we have never been a firm to rest of our laurels. With the support of our parent company Ipca Laboratories, we are very much investing in our physical capacity, equipment and technical resource.
“We remain committed to supporting drug developers across the globe with routine chemistry and overcoming early stage complex chemistry challenges to allow them to progress, scale-up and meet clinical deadline with robust lead candidates.”
This latest venture follows investment last year to grow its GMP space following an increase in demand for its small-scale API manufacturing services.
Established back in 2000, Onyx Scientific now provides clients with the production of API in up to 50 L-100 L equipment under current GMP regulations, which fits with its earlier stage custom synthesis, lead optimisation and analytical services.
Denise added: “The decision to expand into an additional building has been driven by increased demand for GMP services as well as continuous flow projects and solid state chemistry, which has fully utilised our resources over the past 12 months.”
Alongside its work with large pharma, Onyx Scientific is a preferred partner for many specialty drug development firms and biotech organisations, supporting them with rapid progress from lead optimisation through Phase I-II.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance